Favipiravir

Drug Profile

Favipiravir

Alternative Names: Avigan; T-705; T-705a

Latest Information Update: 28 Jun 2016

Price : $50

At a glance

  • Originator Toyama Chemical
  • Developer BioDefense Therapeutics; FUJIFILM Holdings Corporation; FujiFilm Pharmaceuticals USA; INSERM; MediVector; Toyama Chemical
  • Class Amides; Antivirals; Pyrazines; Small molecules
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections
  • Phase I Ebola virus infections

Most Recent Events

  • 22 Jun 2016 Zhejiang Hisun Pharmaceutical in-licenses patent from FUJIFILM to develop, manufacture and market favipiravir in China
  • 15 Apr 2016 Institut National de la Santé Et de la Recherche Médicale plans the phase II FORCE trial for Ebola virus infections in France and Guinea (PO) (NCT02739477)
  • 27 Aug 2015 No recent reports of development identified - Phase-II for Influenza virus infections in Paraguay and Chile (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top